Document Detail


Discontinuing donepezil or starting memantine for Alzheimer's disease.
MedLine Citation:
PMID:  22670912     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
To the Editor: In the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO) study, Howard and coauthors (March 8 issue)(1) found that the magnitude of benefit, as assessed with the Standardized Mini-Mental State Examination (SMMSE) and the Bristol Activities of Daily Living Scale (BADLS), was more favorable in patients who continued donepezil as compared with those who were assigned to memantine. However, only patients who had already received donepezil for more than 3 months were recruited, which plausibly suggests that those in whom donepezil had an unfavorable side-effect profile, and possibly those who did not show any indication . . .
Authors:
Mariel M Finucane; Thomas E Finucane
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The New England journal of medicine     Volume:  366     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-06-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2227-8     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Discontinuing donepezil or starting memantine for Alzheimer's disease.
Next Document:  Prostate-Cancer Mortality after PSA Screening.